利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.01 秒)

    Medicinal compositions for angiogenic therapy
    1.
    发明公开
    Medicinal compositions for angiogenic therapy 有权
    Medizinische Zusammensetzungen zur Angiogenese-Therapie

    公开(公告)号：EP1889633A1

    公开(公告)日：2008-02-20

    申请号：EP07021738.5

    申请日：2001-06-27

    申请人： AnGes MG, Inc. ,  Morishita, Ryuichi

    发明人： The designation of the inventor has not yet been filed

    IPC分类号： A61K45/00 ,  A61K48/00 ,  A61K31/711 ,  A61K38/18 ,  A61K31/5585 ,  A61P9/00 ,  A61P9/10 ,  A61K38/16

    CPC分类号： A61K38/52 ,  A61K31/5585 ,  A61K31/711 ,  A61K38/1709 ,  A61K38/1833 ,  A61K38/1858 ,  A61K48/00 ,  A61K2300/00

    摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

    摘要翻译： 本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）用于增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets-1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管发生剂。

    MEDICINAL COMPOSITIONS FOR ANGIOGENIC THERAPY
    2.
    发明公开
    MEDICINAL COMPOSITIONS FOR ANGIOGENIC THERAPY 有权
    药剂师ZUBEREITUNGEN ZUR ANGIOGENESE-THERAPIE

    公开(公告)号：EP1300158A1

    公开(公告)日：2003-04-09

    申请号：EP01943840.7

    申请日：2001-06-27

    申请人： MedGene Bioscience, Inc. ,  Morishita, Ryuichi

    发明人： MORISHITA, Ryuichi ,  KOIKE, Hiromi ,  TANABE, Tadashi ,  AOKI, Motokuni

    IPC分类号： A61K45/00 ,  A61K48/00 ,  A61K31/711 ,  A61K38/18 ,  A61K31/5585 ,  A61P9/00 ,  A61P9/10

    CPC分类号： A61K38/52 ,  A61K31/5585 ,  A61K31/711 ,  A61K38/1709 ,  A61K38/1833 ,  A61K38/1858 ,  A61K48/00 ,  A61K2300/00

    摘要： The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets-1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

    摘要翻译： 本发明提供：（1）血管生成治疗用药物组合物，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分，以及生成它们的物质; 和编码血管生成因子的基因; （2）用于增强编码血管生成因子的基因的血管生成作用的药剂，其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; （3）含有前列环素合酶基因作为活性成分的血管生成剂; （4）含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; （4）含有ets-1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和（5）含有ets-1基因作为活性成分的血管发生剂。

    PHARMACEUTICAL COMPOSITIONS FOR ANGIOGENIC THERAPY
    3.
    发明授权
    PHARMACEUTICAL COMPOSITIONS FOR ANGIOGENIC THERAPY 有权
    药物制剂血管生成治疗

    公开(公告)号：EP1300158B9

    公开(公告)日：2008-11-19

    申请号：EP01943840.7

    申请日：2001-06-27

    申请人： AnGes MG, Inc. ,  Morishita, Ryuichi

    发明人： MORISHITA, Ryuichi ,  KOIKE, Hiromi ,  TANABE, Tadashi ,  AOKI, Motokuni

    IPC分类号： A61K38/18 ,  A61K38/43 ,  A61P9/00 ,  A61P9/10 ,  C12N15/19 ,  C12N15/52

    CPC分类号： A61K38/52 ,  A61K31/5585 ,  A61K31/711 ,  A61K38/1709 ,  A61K38/1833 ,  A61K38/1858 ,  A61K48/00 ,  A61K2300/00

    摘要： Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same; an angiogenic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and an angiogenic agent which contains ets-1 gene as the active ingredient.

    GENE THERAPY FOR CEREBROVASCULAR DISORDERS
    5.
    发明公开
    GENE THERAPY FOR CEREBROVASCULAR DISORDERS 有权
    GENTHERAPIEFÜRZEREBRALEGEFÄSSERKRANKUNGEN

    公开(公告)号：EP1132098A1

    公开(公告)日：2001-09-12

    申请号：EP00961050.2

    申请日：2000-09-18

    申请人： MedGene Bioscience, Inc. ,  Morishita, Ryuichi

    发明人： MORISHITA, Ryuichi ,  OGIHARA, Toshio

    IPC分类号： A61K48/00 ,  A61K38/18 ,  A61P9/00 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P43/00

    CPC分类号： A61K38/1833 ,  A61K38/1866 ,  A61K48/00

    摘要： By introducing hepatocyte growth factor (HGF) gene and/or vascular endothelial growth factor (VEGF) gene into the subarachnoid space in humans, cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, and Alzheimer's dementia can be effectively treated or prevented.

    摘要翻译： 通过将肝细胞生长因子（HGF）基因和/或血管内皮生长因子（VEGF）基因引入人类的蛛网膜下腔内，脑血管障碍如脑血管梗阻，脑梗死，脑血栓形成，脑栓塞，中风，脑出血，moyamoya病 ，脑血管性痴呆和阿尔茨海默氏痴呆症可以有效地治疗或预防。

    PHARMACEUTICAL COMPOSITIONS FOR ANGIOGENIC THERAPY
    8.
    发明授权
    PHARMACEUTICAL COMPOSITIONS FOR ANGIOGENIC THERAPY 有权
    用于血管生成治疗的药物组合物

    公开(公告)号：EP1300158B1

    公开(公告)日：2008-05-14

    申请号：EP01943840.7

    申请日：2001-06-27

    申请人： AnGes MG, Inc. ,  Morishita, Ryuichi

    发明人： MORISHITA, Ryuichi ,  KOIKE, Hiromi ,  TANABE, Tadashi ,  AOKI, Motokuni

    IPC分类号： A61K38/18 ,  A61K38/43 ,  A61P9/00 ,  A61P9/10 ,  C12N15/19 ,  C12N15/52

    CPC分类号： A61K38/52 ,  A61K31/5585 ,  A61K31/711 ,  A61K38/1709 ,  A61K38/1833 ,  A61K38/1858 ,  A61K48/00 ,  A61K2300/00

    摘要： Medicinal compositions for angiogenic therapy which contain as the active ingredients at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same, and a gene encoding an angiogenesis factor; agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain as the active ingredient at least one member selected from among substances having a vasodilating effect and/or a platelet aggregation inhibitory effect and substances producing the same; an angiogenic agent which contains prostacyclin synthase gene as the active ingredient; medicinal compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; an agent for potentiating the angiogenic effect of a gene encoding an angiogenesis factor which contain ets-1 gene as the active ingredient; and an angiogenic agent which contains ets-1 gene as the active ingredient.

    摘要翻译： 含有选自具有血管舒张作用和/或血小板聚集抑制作用的物质中的至少一种作为有效成分的血管生成疗法用药物组合物及其制造物质和编码血管生成因子的基因， 包含作为活性成分的选自具有血管舒张作用和/或血小板凝集抑制作用的物质中的至少一种的物质和产生该物质的物质的增强编码血管发生因子的基因的血管生成作用的试剂; 含有前列环素合酶基因作为活性成分的血管生成剂; 包含ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; 用于增强编码血管生成因子的基因的血管生成作用的试剂，该基因含有作为活性成分的ets-1基因; 和含有ets-1基因作为活性成分的血管生成剂。

    NEEDLELESS SYRINGE HAVING MEDICAL AGENT ACCOMMODATED THEREIN
    9.
    发明公开
    NEEDLELESS SYRINGE HAVING MEDICAL AGENT ACCOMMODATED THEREIN 审中-公开
    NADELLOSE SPRITZE MIT DARIN AUFGENOMMENEM MEDIZINISCHEN MITTEL

    公开(公告)号：EP1647292A1

    公开(公告)日：2006-04-19

    申请号：EP04730727.7

    申请日：2004-04-30

    申请人： Morishita, Ryuichi ,  AnGes MG, Inc. ,  SHIMADZU CORPORATION

    发明人： MORISHITA, Ryuichi ,  TOMITA, Naruya ,  KUNUGIZA, Yasuo ,  TANIYAMA, Yoshiaki ,  KOIKE, Hiromi ,  UDAGAWA, Haruhide c/o Shimadzu Corporation ,  KIMURA, Tatsuo c/o Shimadzu Corporation

    IPC分类号： A61M5/30 ,  C12N15/00

    CPC分类号： A61M5/30 ,  A61K38/1833 ,  A61K48/00

    摘要： The present invention provides a needleless syringe having, accommodated therein, a pharmaceutical preparation containing genes and/or analogues thereof. A needleless syringe comprising: a medical agent chamber 22 having one or multiple nozzle bore(s) 25 and accommodated with a medical agent L, and a syringe main body 12 being provided with pressure application means 32 to apply pressure on the medical agent L toward a direction of the nozzle bore (s) 25 and effect emission of the medical agent L through the nozzle bore (s) 25, wherein the medical agent L is a pharmaceutical preparation containing genes and/or analogues thereof. Examples of the medical agent L include pharmaceutical preparation containing HGF gene and pharmaceutical preparation containing NF-κB decoy oligonucleotide.

    摘要翻译： 本发明提供了一种无针注射器，其中容纳有含有其基因和/或类似物的药物制剂。 一种无针注射器，包括：具有一个或多个喷嘴孔25并容纳有药剂L的药剂处理室22，以及注射器主体12，其设有施加压力的压力施加装置32，以向药剂L施加压力 喷嘴孔25的方向并且通过喷嘴孔25发射药剂L，其中药剂L是含有其基因和/或类似物的药物制剂。 药剂L的实例包括含有HGF基因的药物制剂和含有NF-κB诱饵寡核苷酸的药物制剂。